Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by University Hospital, Ghent
Information provided by (Responsible Party):
University Hospital, Ghent Identifier:
First received: September 2, 2011
Last updated: June 2, 2015
Last verified: June 2015
In various common cancers, the skeleton is a preferred site of metastasis. These bone metastases are the most common cause of cancer-related pain, which significantly impair quality of life. It is postulated that the clinical target volume (CTV) of painful bone metastases consists of cancer cells and tumor-associated host cells: the tumor-host ecosystem. Advances in biological imaging (positron emitting tomography PET) might allow us to selectively identify the tumor-host ecosystem within the anatomical boundaries of a bone metastasis. These findings suggest the potential of intentionally non-homogenous dose escalation (dose painting by numbers) to improve pain control. The hypothesis is that fluorodeoxyglucose positron emitting tomography (FDG-PET) can detect the intra-bone metastasis regions confined with tumor-associated host-cell compartments responsible for metastasis-related pain. The primary objective is to improve pain control with biological image-guided stereotactic body radiotherapy compared to conventional radiotherapy.

Condition Intervention Phase
Bone Metastases
Radiation: Conventional Radiotherapy
Radiation: Biological image-guided radiotherapy with conventional dose.
Radiation: Biological image-guided SBRT with dose-escalation.
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Level of pain response 1 month after radiotherapy [ Time Frame: 1 month after radiotherapy ]
    Pain is measured with the visual analogue scale. Response is scored in accordance to the guidelines of the international consensus on palliative radiotherapy.

Secondary Outcome Measures:
  • Quality of life 1 month after radiotherapy. [ Time Frame: 1 Month after radiotherapy ]
    Quality of life 1 month after radiotherapy measured with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Bone Metastases Module (QLQ-BM22).

Estimated Enrollment: 120
Study Start Date: February 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Conventional radiotherapy Radiation: Conventional Radiotherapy
Conventional radiotherapy will be used (8 Gy/ 1 fraction).
Experimental: Biological image-guided radiotherapy with conventional dose. Radiation: Biological image-guided radiotherapy with conventional dose.
Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
Experimental: Biological image-guided SBRT with dose-escalation. Radiation: Biological image-guided SBRT with dose-escalation.
Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Painful bone metastasis of solid tumors
  • Pain score minimum of 2 on a scale of 10
  • A maximum number of painful bone metastases: 3 or more
  • Life expectancy > 3 months
  • Age minimum 18 years old
  • Signed informed consent

Exclusion Criteria:

  • Tumor histology (renal cell and melanoma vs. other solid tumors)
  • VAS pain score (<5 vs. 6-10).
  • Bisphosphonate use (yes vs. no)
  • Opioid analgesics (yes vs. no)
  • Corticosteroid use (yes vs. no)
  • Spine vs non-spine localisation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01429493

Contact: Piet Ost, MD 09/3323074

University Hospital Antwerp Recruiting
Antwerp, Belgium
Contact: Dirk Van Gestel, M.D.         
Principal Investigator: Dirk Van Gestel, M.D.         
Ghent University Hospital Recruiting
Ghent, Belgium, 9000
Contact: Wilfried De Neve, MD, PhD    +32(0)93323074 ext +32   
Principal Investigator: Wilfried De Neve, MD, PhD         
Sub-Investigator: Christophe Vandewiele, MD, PhD         
Sub-Investigator: Indira Madani, MD         
Sub-Investigator: Piet Ost, PhD, MD         
Sub-Investigator: Bruno De Potter, MD         
Sponsors and Collaborators
University Hospital, Ghent
Principal Investigator: Wilfried De Neve, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Hospital, Ghent Identifier: NCT01429493     History of Changes
Other Study ID Numbers: 2011/541
Study First Received: September 2, 2011
Last Updated: June 2, 2015

Additional relevant MeSH terms:
Neoplasm Metastasis
Bone Neoplasms
Bone Marrow Diseases
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases processed this record on May 22, 2017